Published in Biochim Biophys Acta on August 08, 1997
Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol (2002) 1.56
Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor. Br J Pharmacol (2004) 1.45
The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol (2000) 1.39
RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol (2000) 1.35
Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol (1999) 1.29
Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes. Hum Mol Genet (2010) 1.13
Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med (2007) 1.13
Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities. J Mol Biol (2009) 1.13
Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci U S A (1999) 1.10
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J Med Chem (2013) 1.04
Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition. Mol Cell Biol (2004) 1.00
Protein farnesyltransferase-catalyzed isoprenoid transfer to peptide depends on lipid size and shape, not hydrophobicity. Chembiochem (2008) 0.99
Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro Oncol (2005) 0.97
Farnesyltransferase inhibitor improved survival following endotoxin challenge in mice. Biochem Biophys Res Commun (2009) 0.96
RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. Cell Growth Differ (2002) 0.95
Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. Proc Natl Acad Sci U S A (1998) 0.95
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis (2015) 0.94
Rig is a novel Ras-related protein and potential neural tumor suppressor. Proc Natl Acad Sci U S A (2002) 0.90
Murine guanylate-binding protein: incomplete geranylgeranyl isoprenoid modification of an interferon-gamma-inducible guanosine triphosphate-binding protein. Mol Biol Cell (2000) 0.90
Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88
New targets for therapy in breast cancer: farnesyltransferase inhibitors. Breast Cancer Res (2004) 0.86
A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. Leukemia (2011) 0.85
Unraveling the mechanism of the farnesyltransferase enzyme. J Biol Inorg Chem (2004) 0.84
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. Cancer (2011) 0.83
Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells. Br J Cancer (2000) 0.83
Biochemical and docking analysis of substrate interactions with polyisoprenylated methylated protein methyl esterase. Curr Cancer Drug Targets (2010) 0.83
Polyisoprenylated methylated protein methyl esterase is both sensitive to curcumin and overexpressed in colorectal cancer: implications for chemoprevention and treatment. Biomed Res Int (2013) 0.82
Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.82
Mechanisms of Chromosome Congression during Mitosis. Biology (Basel) (2017) 0.82
Selective Gas-Phase Oxidation and Localization of Alkylated Cysteine Residues in Polypeptide Ions via Ion/Ion Chemistry. J Proteome Res (2016) 0.80
Isopentenyl-diphosphate isomerase is essential for viability of Caenorhabditis elegans. Mol Genet Genomics (2005) 0.80
Novel prenyl-linked benzophenone substrate analogues of mycobacterial mannosyltransferases. Biochem J (2004) 0.79
Ras-mediated suppression of TGFbetaRII expression in intestinal epithelial cells involves Raf-independent signaling. Neoplasia (2001) 0.78
Enhanced antiproliferative and apoptotic response of HT-29 adenocarcinoma cells to combination of photoactivated hypericin and farnesyltransferase inhibitor manumycin A. Int J Mol Sci (2011) 0.78
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk (2015) 0.78
Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas. Mol Cancer (2008) 0.78
Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitors. Cell Death Discov (2015) 0.77
Identification of a farnesol analog as a Ras function inhibitor using both an in vivo Ras activation sensor and a phenotypic screening approach. Mol Cell Biochem (2013) 0.76
Analogs of farnesyl diphosphate alter CaaX substrate specificity and reactions rates of protein farnesyltransferase. Bioorg Med Chem Lett (2015) 0.76
The extracellular matrix protein EMILIN1 silences the RAS-ERK pathway via α4β1 integrin and decreases tumor cell growth. Oncotarget (2017) 0.75
In Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells. Transl Med UniSa (2016) 0.75
Signaling inhibitors in the treatment of prostate cancer. Invest New Drugs (2002) 0.75
Mutational analysis of the integral membrane methyltransferase isoprenylcysteine carboxyl methyltransferase (ICMT) reveals potential substrate binding sites. J Biol Chem (2014) 0.75
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science (1997) 6.50
Increasing complexity of Ras signaling. Oncogene (1998) 5.71
Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci U S A (1982) 5.39
Biological and biochemical properties of human rasH genes mutated at codon 61. Cell (1986) 5.05
p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci U S A (1989) 4.80
Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol (1995) 4.78
Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature (1997) 4.66
Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science (1988) 4.58
GTP-binding mutants of rab1 and rab2 are potent inhibitors of vesicular transport from the endoplasmic reticulum to the Golgi complex. J Cell Biol (1992) 4.34
Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol (2000) 3.86
Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science (1997) 3.32
Rab1b regulates vesicular transport between the endoplasmic reticulum and successive Golgi compartments. J Cell Biol (1991) 3.22
Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation. Cell (1989) 3.12
Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways. Mol Cell Biol (1997) 3.09
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell (1993) 2.92
The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell (2001) 2.89
Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol (1996) 2.69
The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem (1996) 2.60
Increasing complexity of the Ras signaling pathway. J Biol Chem (1998) 2.56
Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia. J Cell Biol (1995) 2.56
Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem (1997) 2.55
The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr Opin Cell Biol (2000) 2.38
Critical role of Rho in cell transformation by oncogenic Ras. Oncogene (1995) 2.37
Dbl family proteins. Biochim Biophys Acta (1997) 2.36
Altered gene products are associated with activation of cellular rasK genes in human lung and colon carcinomas. Cell (1983) 2.27
The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation. EMBO J (1997) 2.19
Biological assays for Ras transformation. Methods Enzymol (1995) 2.16
Human cell hybrids: analysis of transformation and tumorigenicity. Science (1982) 2.16
The Ras signal transduction pathway. Cancer Metastasis Rev (1994) 2.13
Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A (1992) 2.10
Activation of the cellular proto-oncogene product p21Ras by addition of a myristylation signal. Science (1989) 2.04
Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene (1998) 1.99
Isoprenoid modification of rab proteins terminating in CC or CXC motifs. Proc Natl Acad Sci U S A (1991) 1.99
The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem (1997) 1.98
Lck regulates Vav activation of members of the Rho family of GTPases. Mol Cell Biol (1997) 1.96
GTP binding by class II transactivator: role in nuclear import. Science (1999) 1.94
Vav2 is an activator of Cdc42, Rac1, and RhoA. J Biol Chem (2000) 1.93
Two distinct Raf domains mediate interaction with Ras. J Biol Chem (1995) 1.88
Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci U S A (1990) 1.84
Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway. J Biol Chem (1999) 1.82
Activation of ras genes in human tumors does not affect localization, modification, or nucleotide binding properties of p21. Cell (1984) 1.76
Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat (1995) 1.75
Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem (1995) 1.75
rasH mutants deficient in GTP binding. Mol Cell Biol (1986) 1.73
Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases. Proc Natl Acad Sci U S A (1994) 1.67
The six amino-terminal amino acids of p60src are sufficient to cause myristylation of p21v-ras. Mol Cell Biol (1988) 1.65
Dbl and Vav mediate transformation via mitogen-activated protein kinase pathways that are distinct from those activated by oncogenic Ras. Mol Cell Biol (1994) 1.60
ras-induced neuronal differentiation of PC12 cells: possible involvement of fos and jun. Mol Cell Biol (1989) 1.59
Guanine nucleotide exchange factors: activators of the Ras superfamily of proteins. Bioessays (1995) 1.57
Emerging concepts in the Ras superfamily of GTP-binding proteins. FASEB J (1993) 1.56
Regulation of RasGRP via a phorbol ester-responsive C1 domain. Mol Cell Biol (1998) 1.55
Protein prenylation: more than just glue? Curr Opin Cell Biol (1992) 1.54
Splice variants of intersectin are components of the endocytic machinery in neurons and nonneuronal cells. J Biol Chem (1999) 1.53
The COOH-terminal domain of the Rap1A (Krev-1) protein is isoprenylated and supports transformation by an H-Ras:Rap1A chimeric protein. Mol Cell Biol (1991) 1.52
Biological assays for cellular transformation. Methods Enzymol (1994) 1.51
Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras [corrected]. J Biol Chem (1996) 1.50
Oncogenic Ras can induce transcriptional activation through a variety of promoter elements, including tandem c-Ets-2 binding sites. Oncogene (1994) 1.48
Rho family GTPases regulate mammary epithelium cell growth and metastasis through distinguishable pathways. Mol Med (2001) 1.46
Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. Proc Natl Acad Sci U S A (1996) 1.46
Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett (2001) 1.45
RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. J Biol Chem (2001) 1.44
Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 activation of Ras transforming activity. Proc Natl Acad Sci U S A (1994) 1.44
Rap1A is a substrate for cyclic AMP-dependent protein kinase in human neutrophils. J Immunol (1991) 1.43
R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells. Oncogene (1994) 1.42
Ras interaction with two distinct binding domains in Raf-1 may be required for Ras transformation. J Biol Chem (1996) 1.42
Molecular basis for Rac1 recognition by guanine nucleotide exchange factors. Nat Struct Biol (2001) 1.39
Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. Mol Cell Biol (1992) 1.39
Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation. J Biol Chem (1996) 1.39
Identification and characterization of Src SH3 ligands from phage-displayed random peptide libraries. J Biol Chem (1994) 1.39
Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of RhoA. J Biol Chem (2001) 1.39
Dependence of Dbl and Dbs transformation on MEK and NF-kappaB activation. Mol Cell Biol (1999) 1.38
Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J Biol Chem (1999) 1.38
Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev (2009) 1.36
Isolation of a NCK-associated kinase, PRK2, an SH3-binding protein and potential effector of Rho protein signaling. J Biol Chem (1996) 1.32
M-Ras/R-Ras3, a transforming ras protein regulated by Sos1, GRF1, and p120 Ras GTPase-activating protein, interacts with the putative Ras effector AF6. J Biol Chem (1999) 1.30
The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. Oncogene (2001) 1.29
R-Ras promotes apoptosis caused by growth factor deprivation via a Bcl-2 suppressible mechanism. J Cell Biol (1995) 1.29
Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene (1996) 1.25
Quantitative analysis of the effect of phosphoinositide interactions on the function of Dbl family proteins. J Biol Chem (2001) 1.22
Ras-15A protein shares highly similar dominant-negative biological properties with Ras-17N and forms a stable, guanine-nucleotide resistant complex with CDC25 exchange factor. Oncogene (1994) 1.22
Identification of residues critical for Ras(17N) growth-inhibitory phenotype and for Ras interaction with guanine nucleotide exchange factors. Mol Cell Biol (1994) 1.21
Ras (CXXX) and Rab (CC/CXC) prenylation signal sequences are unique and functionally distinct. J Biol Chem (1992) 1.20
Novel determinants of H-Ras plasma membrane localization and transformation. Oncogene (1996) 1.20
Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ (1992) 1.20
Activation of phospholipase C-epsilon by heterotrimeric G protein betagamma-subunits. J Biol Chem (2001) 1.19
A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J Biol Chem (1997) 1.18
14-3-3 zeta negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain. J Biol Chem (1997) 1.17
Functional interaction between the cytoplasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF. Curr Biol (1999) 1.17
Biological and structural characterization of a Ras transforming mutation at the phenylalanine-156 residue, which is conserved in all members of the Ras superfamily. Proc Natl Acad Sci U S A (1995) 1.16
Suppression of tumorigenicity with continued expression of the c-Ha-ras oncogene in EJ bladder carcinoma-human fibroblast hybrid cells. Proc Natl Acad Sci U S A (1986) 1.16
Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase. Mol Cell Biol (2001) 1.15
Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. Oncogene (2009) 1.14
Elucidation of binding determinants and functional consequences of Ras/Raf-cysteine-rich domain interactions. J Biol Chem (2000) 1.14
Transforming potential of Dbl family proteins correlates with transcription from the cyclin D1 promoter but not with activation of Jun NH2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun. J Biol Chem (1998) 1.14
Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation. Mol Cell Biol (1994) 1.13
Biochemical characterization of baculovirus-expressed rap1A/Krev-1 and its regulation by GTPase-activating proteins. Mol Cell Biol (1990) 1.13
CDC42 and FGD1 cause distinct signaling and transforming activities. Mol Cell Biol (1998) 1.13
p120 GAP modulates Ras activation of Jun kinases and transformation. J Biol Chem (1997) 1.13
p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene (2009) 1.12